Products esmirtazapine + Placebo
esmirtazapine + Placebo Phase 3 Completed 📈 Rising Menopause, Vasomotor Symptoms
Oct 15, 2004 → Jan 15, 2006
About esmirtazapine + Placebo esmirtazapine + Placebo is a phase 3 stage product being developed by Merck for Menopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00560833. Target conditions include Menopause, Vasomotor Symptoms.
Clinical Trials (6) NCT ID Phase Status Start Completion Indication NCT00631657 Phase 3 Completed Mar 4, 2008 Nov 19, 2009 Sleep Initiation and Maintenance Disorders NCT00561821 Phase 3 Completed Nov 20, 2007 Dec 21, 2009 Insomnia NCT00506389 Phase 3 Completed Jun 6, 2007 Feb 13, 2008 Insomnia NCT00482612 Phase 3 Completed Dec 7, 2006 Aug 11, 2008 Insomnia NCT00560833 Phase 3 Completed Oct 15, 2004 Jan 15, 2006 Menopause NCT00535288 Phase 3 Completed Sep 15, 2004 Jan 15, 2006 Postmenopausal Symptoms
Product Company Stage Hype Score atomoxetine + placebo Eli Lilly Pre-clinical Fezolinetant + Placebo Astellas Pharma Phase 2 Cetrorelix Shionogi Pre-clinical Teriparatide (PTH 1-34) Eli Lilly Phase 2/3 Eszopiclone + Placebo Sumitomo Pharma Pre-clinical Comparator: placebo + Comparator: Estrace Merck Phase 1 Marketed low dose hormone replacement therapy Novo Nordisk Pre-clinical 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) Novo Nordisk Pre-clinical 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA) Novo Nordisk Approved estradiol, 10 mcg + estradiol, 25 mcg + placebo Novo Nordisk Phase 3 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) + 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) + 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA) Novo Nordisk Phase 1 estradiol, 25 mcg Novo Nordisk Pre-clinical estradiol, 10 mcg Novo Nordisk Phase 3 estradiol, 10 mcg + estradiol, 25 mcg Novo Nordisk Phase 1 estradiol, 10 mcg Novo Nordisk Phase 3 2 mg estradiol / 1 mg norethisterone acetate (NETA) Novo Nordisk Phase 1 estradiol, 25 mcg Novo Nordisk Phase 3 estradiol, 25 mcg Novo Nordisk Phase 3 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) + 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) + placebo Novo Nordisk Phase 3 estradiol, 25 mcg + estradiol, 25 mcg Novo Nordisk Phase 1
Other Products from Merck